# Clinical Study on the Intervention of Xuesaitong Soft Capsules in Post-Intervention Patients with Acute Coronary Syndrome and Clinical Research Protocol

Study · id `cardio:ct-nct06845254` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT06845254](<https://clinicaltrials.gov/study/NCT06845254>), retrieved 31 October 2026. No person wrote or checked this page.

Also called: NCT06845254

Browse, organ or system: Heart  
Browse, condition area: Coronary and vascular disease  

## In plain language

A phase 3 trial registered on ClinicalTrials.gov. The registry status is not yet recruiting. It plans to enroll 400 participants.

## Technical summary

Registry record NCT06845254. Randomized; double masking; primary purpose treatment. Start 2025-03-01 (anticipated); primary completion 2025-10-01 (anticipated). Results not posted.

## Key facts

- Design: Interventional study; randomized; double masking; primary purpose treatment
- Phase: Phase 3
- Enrolled: 400 participants (planned count; ClinicalTrials.gov record NCT06845254, source copy `cardio:ctgov-nct06845254-2025-02-25`, retrieved 2026-10-31)
- Planned start: 2025-03-01 (anticipated) (ClinicalTrials.gov record NCT06845254, source copy `cardio:ctgov-nct06845254-2025-02-25`, retrieved 2026-10-31)
- Primary completion: 2025-10-01 (anticipated) (ClinicalTrials.gov record NCT06845254, source copy `cardio:ctgov-nct06845254-2025-02-25`, retrieved 2026-10-31)
- Completion: 2026-12-01 (anticipated) (ClinicalTrials.gov record NCT06845254, source copy `cardio:ctgov-nct06845254-2025-02-25`, retrieved 2026-10-31)
- Countries: China (ClinicalTrials.gov record NCT06845254, source copy `cardio:ctgov-nct06845254-2025-02-25`, retrieved 2026-10-31)
- Care setting: Not reported
- Registry status: "NOT\_YET\_RECRUITING" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct06845254-2025-02-25`, retrieved 2026-10-31)

## The registry's words

- Brief title: Clinical Study on the Intervention of Xuesaitong Soft Capsules in Post-Intervention Patients with Acute Coronary Syndrome and Clinical Research Protocol
- Condition: Acute Coronary Syndrome
- Intervention (Drug): Xuesaitong soft capsule (main ingredient is Panax notoginseng saponins)
- Intervention (Drug): placebo capsule
- Lead sponsor: Xiyuan Hospital of China Academy of Chinese Medical Sciences
- Lead sponsor class: OTHER

## Connected pages

- Registry condition terms include this condition: Acute coronary syndrome (`cardio:acute-coronary-syndrome`)
- Registry lists this organization as the lead sponsor: Xiyuan Hospital of China Academy of Chinese Medical Sciences (`cardio:org-xiyuan-hospital-of-china-academy-of-chinese-medical-sciences`)

## Provenance

Content hash: e4c4e813fbdc3c2665bf5321f3db84a50730b49b3f90326568bdcacac3a11e58
Last substantive edit: 2026-11-08
Evidence last checked: Not recorded
